8-K: Kestra Medical Technologies Reports Strong Q2 FY26 Results

Kestra Medical Technologies announced robust second-quarter fiscal 2026 financial results, featuring significant revenue growth and expanded gross margins, alongside an upward revision of its full-year revenue guidance.

Summary

• Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.
• Expanded gross margin to 50.6% in Q2 FY26, up from 39.6% in the prior year period.
• Reported 4,696 prescriptions for the ASSURE system, a 54% increase compared to the prior year period.
• GAAP net loss and comprehensive loss was $32.8 million in Q2 FY26, compared to $20.6 million in the prior year period.
• Adjusted EBITDA loss was $19.7 million in Q2 FY26, compared to $16.1 million in the prior year period.
• Cash and cash equivalents totaled $175 million as of October 31, 2025.
• Received $148 million in net proceeds from an underwritten public offering of 6.9 million common shares, which closed on December 4, 2025.
• Increased FY26 revenue guidance to $91 million, representing 52% growth compared to FY25, up from prior guidance of $88 million and initial guidance of $85 million.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant revenue growth and gross margin expansion, coupled with an upward revision of full-year guidance. While net losses increased, this is attributed to commercial expansion and public company costs, indicating investment for future growth. The successful equity offering also fortified the balance sheet.

Positives

• Total revenue increased by 53% to $22.6 million in Q2 FY26, demonstrating strong top-line growth.
• Gross margin expanded significantly to 50.6% from 39.6% in the prior year period, driven by volume leverage and a higher mix of in-network patients.
• Prescriptions for the ASSURE system grew by 54% to 4,696, indicating strong product adoption.
• Revenue growth was driven by higher market share and continued Wearable Cardioverter Defibrillator (WCD) market expansion.
• Improvements in revenue cycle management capabilities contributed to revenue growth.
• The company fortified its balance sheet with $148 million in net proceeds from an equity offering.
• Increased FY26 revenue guidance to $91 million, reflecting confidence in future performance.
• Announced compelling primary results from its post-approval study at the American Heart Association annual meeting.

Negatives

• GAAP operating expenses increased to $43.2 million in Q2 FY26 from $25.0 million in the prior year period, primarily due to commercial expansion and public company costs.
• GAAP net loss and comprehensive loss widened to $32.8 million in Q2 FY26 from $20.6 million in the prior year period.
• Adjusted EBITDA loss increased to $19.7 million in Q2 FY26 from $16.1 million in the prior year period.

Risks

• Risks related to limited operating history and history of net losses.
• Ability to successfully achieve substantial market adoption of products.
• Competitive pressures within the wearable medical device market.
• Ability to adapt manufacturing and production capacities to evolving demand, governmental actions, and customer trends.
• Potential for product defects or complaints and related liability.
• Ability to obtain and maintain adequate coverage and reimbursement levels for products.
• Ability to comply with changing laws and regulatory requirements and resulting costs.
• Dependence on a limited number of suppliers.
• General risks and uncertainties related to market conditions.

Future Outlook

Kestra is increasing its fiscal year 2026 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. This is an increase from prior guidance of $88 million and initial guidance of $85 million. Management remains focused on growing the wearable defibrillator market and executing on its commitments to patients and their prescribers.

Management Comments

• "Kestra delivered another strong quarter of financial performance, generating revenue growth of 53% while expanding gross margin to over 50%, an important milestone for the company."
• "We also continued to make progress on several key operational objectives, including growing the commercial organization, announcing compelling primary results from our post-approval study at the American Heart Association annual meeting, and fortifying our balance sheet with an equity offering earlier this month."
• "As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers."

Industry Context

Kestra Medical Technologies operates in the dynamic wearable medical device and digital healthcare sector, focusing on cardiovascular disease. The company's strong revenue growth and increased market share indicate successful penetration and expansion within the Wearable Cardioverter Defibrillator (WCD) market, aligning with broader trends towards remote patient monitoring and advanced therapeutic interventions.

Stakeholder Impact

• Shareholders: Impacted by the recent equity offering (potential dilution) and the company's strong revenue growth and increased guidance, which could positively influence stock valuation despite ongoing losses.
• Patients and Prescribers: Benefit from the company's focus on expanding the wearable defibrillator market and the positive results from the post-approval study of the ASSURE system, indicating continued product development and efficacy.
• Employees: Affected by the growth in the commercial organization and overall company expansion, potentially leading to new opportunities and increased workload.

Next Steps

• Host a conference call on December 11, 2025, at 4:30 p.m. ET to discuss financial results.
• Continue growing the commercial organization.
• Execute on commitments to patients and prescribers.
• Focus on growing the wearable defibrillator market.

Key Dates

Recommendation

While Kestra Medical Technologies demonstrated impressive revenue growth of 53% and significant gross margin expansion to 50.6%, alongside an increased FY26 revenue guidance, the company continues to report substantial GAAP net losses ($32.8 million) and Adjusted EBITDA losses ($19.7 million). The recent $148 million equity offering fortified the balance sheet, providing capital for continued expansion. The strong top-line growth and market expansion are positive indicators, but the ongoing losses suggest the company is still in a heavy investment phase. A 'hold' recommendation is appropriate for investors to monitor the company's progress in converting revenue growth into profitability while acknowledging its strong market position and growth trajectory.

Keywords

Kestra Medical Technologies, KMTS, wearable defibrillator, digital healthcare, Q2 FY26, financial results, revenue growth, gross margin, equity offering, ASSURE system, medical device, cardiovascular disease